One of the most successful tyrosine kinases inhibitors in cancer treatment is the BCR-ABL inhibitor Imatinib, an effective first-line therapy for patients with chronic myeloid leukemia (CML) [26,27,28]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.